A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Bayer
Seagen Inc.
Seagen Inc.
Pliant Therapeutics, Inc.
Pfizer
Eli Lilly and Company
Compass Therapeutics
Merck Sharp & Dohme LLC
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Exelixis
National Cancer Institute (NCI)
Amgen
EMD Serono
The Methodist Hospital Research Institute
National Institutes of Health Clinical Center (CC)
Bayer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Sotio Biotech Inc.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Rondo Therapeutics
Mayo Clinic
Dragonfly Therapeutics
Merck Sharp & Dohme LLC
Pfizer
Memorial Sloan Kettering Cancer Center
Emory University
M.D. Anderson Cancer Center
Incendia Therapeutics
Tizona Therapeutics, Inc
Shanghai Henlius Biotech
Amgen
University of Rochester
Werewolf Therapeutics, Inc.
Royal Marsden NHS Foundation Trust
M.D. Anderson Cancer Center
Royal Marsden NHS Foundation Trust
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Novartis
Bio-Thera Solutions
AbelZeta Inc.
TILT Biotherapeutics Ltd.
Amgen
Sairopa B.V.
Rutgers, The State University of New Jersey
Abramson Cancer Center at Penn Medicine